Surgery Partners, Inc. (SGRY) Stock Forecast
SGRY analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.42 / 5 from 12 analysts
- Price target
- $18.82 average of analyst targets
- Upside to target
- +28.8% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.03
- 52-week range
- $11.49 – $22.94
SGRY analyst ratings
12 analystsNumber of analysts at each rating.
SGRY price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SGRY earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.12 | $0.10 | $0.16 | $0.13 | −5.8% | 4 |
| Current fiscal year (2026) | $0.35 | $0.24 | $0.47 | $0.47 | −25.5% | 4 |
| Next fiscal year (2027) | $0.28 | $0.17 | $0.46 | $0.35 | −20.0% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SGRY revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $796.2M | $718.7M | $825.0M | −3.1% | 4 |
| Current fiscal year (2026) | $3.15B | $3.10B | $3.18B | −4.9% | 4 |
| Next fiscal year (2027) | $2.81B | $2.76B | $2.88B | −10.7% | 5 |
SGRY EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SGRY revenue: reported and forecast
SGRY EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.13 | $0.13 | $0.13 | $0.12 | $0.12 | −5.8% | 2 up · 2 down |
| Current fiscal year (2026) | $0.45 | $0.46 | $0.49 | $0.35 | $0.35 | −21.7% | 0 up · 4 down |
| Next fiscal year (2027) | $0.65 | $0.67 | $0.63 | $0.28 | $0.28 | −57.2% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SGRY earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SGRY beat in 8 of 12.
What analysts expect from SGRY
12 analysts cover Surgery Partners; their consensus rating is buy (4.42 on a 1–5 scale, where 5 is a strong buy). The average price target is $18.82, 28.8% above the latest close of $14.61. Analysts expect earnings of $0.35 per share for 2026, −25.5% from a year earlier. For 2027 the average estimate is $0.28 per share on revenue of $2.8 billion. Surgery Partners beat the EPS estimate in 8 of the last 12 quarters.
Related: SGRY income statement, SGRY key metrics, SGRY chart. See the SGRY stock overview for the latest quote and news.
SGRY forecast FAQ
What is Surgery Partners's price target?
The average analyst price target for Surgery Partners is $18.82, 28.8% above the latest close of $14.61.
Is Surgery Partners a buy, hold or sell?
Of 12 analysts covering Surgery Partners, 8 rate it a strong buy, 1 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Surgery Partners's EPS forecast?
Analysts forecast $0.35 per share for 2026 (range $0.24 to $0.47); for 2027 the estimate is $0.28.
What is Surgery Partners's revenue forecast?
The average revenue estimate for 2026 is $3.1 billion, growth of −4.9%; for 2027 it is $2.8 billion.
When does Surgery Partners report earnings?
Surgery Partners is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens; the EPS estimate is $-0.03.
Does Surgery Partners usually beat earnings estimates?
Surgery Partners reported EPS at or above the analyst estimate in 8 of the last 12 quarters.